Company intelligence
Lyterian Therapeutics
Co-opting physiologically relevant protein homeostatic mechanisms for treating disease
About Lyterian Therapeutics
Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
Verified activity
Signals from Lyterian Therapeutics
4 published signals
People
Lyterian Therapeutics welcomed Michael Heider to start his own group and treat patients back home in Munich after completing a postdoc stay.
Reported by Michael Rape
People
Lyterian Therapeutics welcomed Conor McClune as the first Assistant Professor in MolecularTherapeutics at the University of California, Berkeley.
Reported by Michael Rape
Presence & Recognition
Lyterian Therapeutics attended the MolecularTherapeutics retreat hosted by Stephen Hauser of the University of California, San Francisco, where he delivered a keynote on basic science and therapies.
Reported by Michael Rape
Presence & Recognition
Lyterian Therapeutics participated in the 5th annual retreat of the MolecularTherapeutics division in the UC Berkeley Department of Molecular and Cell Biology.
Reported by Michael Rape